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Abstract
Background: Epidemiologic data indicates that rheumatoid arthritis is an independent risk factor for cardiovascular disease. 
Epicardial adipose tissue is a novel cardio-metabolic risk factor. Our aim was to evaluate epicardial fat thickness (EFT) using 
echocardiography in patients with rheumatoid arthritis compared to healthy control subjects. Secondly, we investigated rela-
tionship between epicardial fat thickness and clinical and echocardiographic parameters in patients with rheumatoid arthritis.
Method: The study population included 76 consecutive patients with rheumatoid arthritis (64 female; mean age, 53 ±11 
years, median disease duration, 7.8 years) and 50 healthy subjects as controls (39 female; mean age, 52 ± 6 years). All patients 
underwent echocardiography to assess left ventricular diastolic dysfunction, left ventricular hypertrophy and EFT. All values 
were compared between groups.
Results: EFT was higher in rheumatoid arthritis patients than in  healthy controls (0.66±0.20 vs. 0.54±0.18; p= 0.003). 
Thickness of   Intra Ventricular Septum (IVS) (1.1±0.06 and 9.8±0.08; p=0.001) and posterior wall (PW) (0.98±0.05 and 
0.93±0.08; p=0.015) was higher in patients with rheumatoid arthritis compared to healthy controls. Early diastolic myocar-
diac  peak velocity  or late diastolic mitral peak velocity (E/A) ratio was lower in rheumatoid arthritis patients compared 
to healthy patients (1.1 ±0.8 and 1.24±0.1 p=0.001) as well as, E/e’ was higher in Rheumatoid arthritis (RA) patients than 
healthy patients. (E/e’:8.7±1.6 and 8.0±1.4 p=0.020). In patients with rheumatoid arthritis, EFT was positively correlated 
with hypertension and duration of  disease and E/e’ (r: 0.10, p: 0.010, r: 0.306, p: 0.004 and r: 0.465 p: 0.007 respectively) and 
EFT was negatively correlated with E/A (r: -.262 p:0.022 )  
Conclusion: To our knowledge, this is the first report about epicardial adipose tissue in rheumatoid arthritis patients. Epi-
cardial fat thickness as an indicator of  cardiovascular involvement was higher in rheumatoid arthritis patients.
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Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory 
disease characterized by chronic symmetric and erosive 
synovitis that preferentially  affects peripheral joints, 
with  prevalence of  0.5– 1% in the population1. Epide-
miologic data indicates that RA is an independent risk 
factor for cardiovascular disease (CVD)2,3.  Emerging 
epidemiological evidence showed that CVDs account 
for approximately 50% of  all RA associated deaths4. 
Epicardial adipose tissue (EAT), a type of  visceral ad-
ipose tissue, is considered to play a pivotal role in the 
pathogenesis of  coronary artery disease (CAD). Re-
cently, several studies have demonstrated that epicardial 
fat is associated with insulin resistance5, increased car-
dio-metabolic risk6, inflammatory markers7,8 and cor-
onary artery disease9,10. The echocardiographic meas-
urement of  EAT, is an objective, noninvasive, readily 
available, and less expensive measure than magnetic 
resonance imaging or computed tomography. 
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Our aim was to evaluate epicardial fat thickness (EFT) 
using echocardiography in patients with rheumatoid ar-
thritis compared to healthy control subjects. Secondly, 
we investigated the relationship between EFT and clin-





The study population included 76 consecutive patients 
with rheumatoid arthritis (64 female; mean age, 53 ±11 
years, and median disease duration, 7.8 years) and 50 
healthy subjects as controls (39 female; mean age, 52± 6 
years). All patients met the American College of  Rheu-
matology’s grading criteria for a diagnosis of  RA11. A 
detailed history and analysis of  patients was performed. 
The inclusion criteria for the study groups were: age 
≥18 years, patient’s informed consent, absence of  any 
acute disease. Patients with any of  the following fea-
tures were excluded from participation: patients with 
valvular heart  disease; chronic obstructive pulmonary 
disease, any other significant systemic disease, obstruc-
tive coronary artery disease, history of  heart failure, 
hepatic failure, hypertension, serum creatinine >1.4 
mg/dL, patients with a history of  diabetes mellitus (or 
fasting blood glucose >125 mg/dL), pregnant women, 
patients with hypo or hyperthyroidism, patients with 
a BMI >25 kg/m2, and patients who wished to con-
sume alcohol during the study period. Also, we exclud-
ed patients with : heart failure, significant valvular heart 
disease, pacemaker implantation, atrial flutter or fibril-
lation, frequent ventricular pre-excitation and atrioven-
tricular conduction abnormalities, renal failure, previ-
ous myocardial infarction, or cerebrovascular accident 
and poor echocardiographic imaging. 
This study was conducted in accordance with the Dec-
laration of  Helsinki and was approved by our local eth-
ics committee. Informed consent for the procedure was 
obtained from each patient. 
Echocardiography
All patients underwent echocardiography. Following 
a resting period of  15 min, all the patients underwent 
two-dimensional and Doppler echocardiographic eval-
uation, including tissue Doppler imaging (TDI) with 
the echocardiogram device using a 3.5-MHz transduc-
er. Echocardiograms of  all patients were recorded as 
standard parasternal and apical images with the patients 
lying in the left lateral position. The measurement and 
recordings were carried out as normal inspiratory and 
end-expiratory. Doppler records of  M-mode, pulse and 
continuous waves were obtained for each case. All the 
measurements were performed based on the stand-
ards of  the American Society of  Echocardiography by 
the same cardiologist. Left atrial diameter (LAD), left 
ventricular end-diastolic diameter (LVEDD), ejection 
fraction (EF), intraventricular septum thickness (IVS), 
posterior wall thickness (PW) values were defined from 
the recordings obtained with the conventional echo-
cardiography. In the pulsed-wave echocardiographic 
transmittal flow screenings, early diastolic mitral peak 
velocity (E), late diastolic mitral peak velocity (A), were 
measured based on the reference images of  the apical 
4 chamber. On TDI, early diastolic myocardial peak ve-
locity (é) was recorded with apical 4-chamber images 
using a sampling volume of  5 mm in the septal and lat-
eral mitral annular regions. All Doppler measurements 
were carried out manually E/A, and E/é.
Epicardial fat thickness was evaluated on the free wall 
of  the right ventricle from the parasternal long-axis 
view, using the aortic annulus as an anatomic reference. 
Epicardial fat thickness, identified as an echo-free space 
between the myocardium and visceral pericardium on 
two-dimensional echocardiography, was measured per-
pendicularly, ahead of  the right ventricular free wall, at 
the end of  diastole, for three cardiac cycles12.
Laboratory 
Blood samples were drawn by venipuncture to measure 
routine blood chemistry parameters after fasting for at 
least eight hours. Fasting blood glucose, serum creati-
nine, total cholesterol, high-density lipoprotein choles-
terol, low-density lipoprotein cholesterol, and triglycer-
ide levels were recorded. Glucose, creatinine, and lipid 
profile were determined using standard methods.
Statistical analysis 
The statistical analyis  was performed using software 
(SPSS 18.0). Parametric values were given as mean ± 
standard deviation and non-parametric values were 
given as a percentage. To compare parametric continu-
ous variables, the Student's t-test was used; to compare 
nonparametric continuous variables, the Mann–Whit-
ney U-test was used. Categorical data was compared by 
the Chi-square distribution. Correlation analysis was 
performed to determine the relationship between epi-
cardial fat tissue and other cardio-metabolic risk factor. 
Two-tailed P-values of  less than 0.05 were considered 
to indicate statistical significance.
Results
Clinical Features
According to the basic clinical and demographic char-
acteristics, both groups of  the study were similar with 
regard to age, body mass index, fasting glucose, hyper-
tension, diabetes mellitus, and smoking status (table 1). 







(n=50) P value 
Age 53 ± 11 52 ± 6 0.430 
Gender (Female) 64   84% 39   78% 0.257 
Diabetes mellitus, % 8   10% 6   11% 0.105 
Hypertension, % 35    47%         21      43% 0.401 
Smoking, % 7   9.2%       6        12.2% 0.416 
Rheumatoid factor 23.7 (1.0-200) -  
Disease duration, years 7.84 (2.4-30) -  
Steroid use, n 29   (38%) -  
C-reactive protein, mg/dl 19.2 ± 46.3 1.7 ± 3.7 0.007 
Body mass Index 32 ± 6 34 ± 8  0.122 
Waist circumstance   101.12±13.62 103.18±14.53 0.424 
Glucose, mg/dl 93.18±16.83 98.7333±13.26 0.770 
Triglyceride, mg/dl 137.75±52.29 149.41±60.99 0.360 
High density lipoprotein, mg/dl 42.87±6.98 41.81±7.0 0.494 
Total cholesterol, mg/dl 203.70±53.70 211.31±47.38 0.529 
     Low density lipoprotein, mg/dl 126.62±34.28 122.16±33.384 0.553 
  









Comparison of  the baseline echocardiographic values 
among rheumatoid arthritis patients and healthy con-
trols are shown in table 2. Thickness of  IVS (1.1±0.06 
and 9.8±0.08; p=0.001) and PW (0.98±0.05 and 
0.93±0.08; p=0.015) were higher in patients with rheu-
matoid arthritis compared to healthy controls. 
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(n=50) P value 
Epicardial fat thickness,cm 0.66 ± 0.20 0.54 ± 0.18 0.003 
Ejection fraction,  % 63 ± 6 62 ± 4 0.733 
LVEDD,cm 4.5±0.31 4.4±0.27 0.536 
LAD,cm 3.43±0.42 3.46±0.52 0.647 
IVS,cm 1.1±0.06 0.98±0.08 0.010 
PW, cm 0.98±0.05 0.93±0.08 0.015 
Diastolic function 
   E cm/s 74±10 86±12 0.001 
   A cm/s 76±14 73±9 0.140 
   E/A    1.1±0.8 1.24±0.1 0.001 
   e’ cm/s   8.6±1.5 11±1.6 0.001 
   E/e’ 8.7 ±1.6 8.0 ± 1.4 0.020 
 
 
E wave and E/A ratio was lower in rheumatoid arthri-
tis patients compared to healthy patients (E: 74±10 
and 86±12 p=0.01 vs E/A: 1.1 ±0.8 and 1.24±0.1 
p=0.001) as well as, E/e’ was higher in RA patients than 
non-rheumatoid arthritis patients. (E/e’:8.7±1.6 and 
8.0±1.4 p=0.020). EFT was higher in rheumatoid ar-
thritis patients compared to healthy controls (0.66±0.20 
vs. 0.54±0.18; p:0.003). In patients with rheumatoid 
arthritis, EFT was positively correlated with hyperten-
sion and duration of  disease and E/e’ (r: 0.10 p:0.010, 
r:0.306 p: 0.004 and r:0.465 p: 0.007 respectively) (Fig-
ure 1) and EFT was negatively correlated with e/a (r: 
-.262 p:0.022 and)  (Figure 2). 
Left ventricular diastolic dysfunction was detected in 
30 (39%) of  75 patients with rheumatoid arthritis; 24 
patients presented with diastolic dysfunction I and 6 pa-
tients presented with diastolic dysfunction II.
 
Discussion
In our study, we showed that EFT was higher in pa-
tients with rheumatoid arthritis than in  the healthy 
control. Secondly, we demonstrated that left ventricular 
wall thickness and diastolic dysfunction were higher and 
EFT was well correlated with diastolic dysfunction and 
disease duration in patients with rheumatoid arthritis. 
These findings may be associated with cardiovascular 
involvement in patients with rheumatoid arthritis.
Rheumatoid arthritis is linked with an increase in mor-
tality because of  stimulation of  coronary and cerebro-
vascular atherosclerosis.13 Emerging epidemiological 
evidence showed that CVDs account for approximate-
ly 50% of  all RA associated deaths4.  EAT, a type of  
visceral adipose tissue, is thought to play a pivotal role 
in the pathogenesis of  coronary artery disease (CAD). 
EAT releases a wide range of  biologically active mol-
ecules that modulate vascular smooth-muscle contrac-
tion. Their paracrine effects might be attributable to 
their location being close to the adventitia and extravas-
cular bed14-16 Gastaldelli et al.16 reported the existence of  
a link between EAT and hypertension, atherosclerosis, 
and coronary heart disease. Nakanishi and colleagues17 
reported that increased epicardial fat volume measured 
by CT is associated with greater progression of  cor-
onary artery calcification. Transthoracic echocardiog-
raphy provides non-invasive assessment of  EFT6, 12. 
Several studies have emphasized the link between EFT 
and the severity of  coronary artery disease (CAD)19-21. 
EFT has an important role in the inflammatory pro-
cess within the atherosclerotic plaque9. In our study, 
we demonstrated that EFT was higher in patients with 
rheumatoid arthritis. In addition , we showed that EFT 
was associated with duration of  disease, hypertension, 
and diastolic dysfunction in patients with rheumatoid 
arthritis. These findings indicate that rheumatoid arthri-
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Figure 1 
Isolated diastolic dysfunction is related to  prominent 
increase in all-cause mortality in the general popula-
tion22,23. Left ventricular diastolic dysfunction (LVDD) 
is frequently related to common structural abnormali-
ties, such as  hypertrophy or interstitial fibrosis, and im-
paired myocyte  relaxation due to ischemia24. Previous 
studies showed the existence of  LVDD in patients with 
RA without clinically prominent cardiac disease.25-27. 
Liang et al. investigated the prevalence of  LVDD in 
patients with RA. They found that patients with RA 
have a higher prevalence of  LVDD than those healthy 
controls and RA duration is also independently associ-
ated with LVDD28. In our study, LVDD was detected 
in 30 (39%) of  75 patients with rheumatoid arthritis; 
24 patients presented with diastolic dysfunction I and 
6 patients presented with diastolic dysfunction II. Ru-
dominer et al. showed that left ventricular hypertrophy 
is higher compared to healthy patients3. LV hypertro-
phy predicts cardiovascular outcomes independent of  
traditional risk factors30-32.  In our study, we found  that 
left ventricular wall thickness was increased in patients 
with rheumatoid arthritis.
The use of  the Doppler echocardiography technique 
to evaluate  left ventricular filling by trans-mitral flow 
is considered a reliable method.2 The relation between 
trans-mitral flow variation and disease duration in 
rheumatoid arthritis indicate a subclinical myocardial 
involvement.25  In our study, we showed that diastolic 
function in patients with rheumatoid arthritis was im-
paired compared to those healthy patients. In addition, 
we demonstrated that  disease duration in patients with 
rheumatoid arthritis was associated with diastolic dys-
function: consistent with previous studies.
Limitations
Some limitations of  this study are evident. The primary 
limitation of  our study was the small sample size. A 
small sample size has low statistical power and, thus, 
may yield false-negative results.  The other limitation of  
our study is its cross-sectional design.  The results can-
not be generalized to the general population. Neither 
can we apply our results to the general population due 
to the numerous  exclusion criteria. Despite this, we  be-
lieve that our findings provide a valuable contribution 
to the EFT and RA. Future prospective much larger 
multicenter studies are required to confirm our results.
   
Conclusion
Epicardial  fat thickness as an indicator of  cardiovascu-
lar involvement was higher in patients with rheumatoid 
arthritis. Also, we showed that diastolic dysfunction and 
left ventricular hypertrophy were higher in rheumatoid 
arthritis patients. These findings suggest that subclinical 
cardiac involvement in patients with RA and those pa-
tients may be underlying risk factors for  development 
of   cardiovascular disease. 
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